David Moatazedi
Net Worth

Last updated:

What is David Moatazedi net worth?

The estimated net worth of Mr. David Moatazedi is at least $21,111,503 as of 23 Dec 2024. He owns shares worth $3,712,214 as insider, has earned $12,399,289 from insider trading and has received compensation worth at least $5,000,000 in Evolus, Inc..

What is the salary of David Moatazedi?

Mr. David Moatazedi salary is $1,250,000 per year as Pres, Chief Executive Officer & Director in Evolus, Inc..

How old is David Moatazedi?

Mr. David Moatazedi is 47 years old, born in 1978.

What stocks does David Moatazedi currently own?

As insider, Mr. David Moatazedi owns shares in one company:

Company Title Shares Price per share Total value
Evolus, Inc. (EOLS) Pres, Chief Executive Officer & Director 522,847 $7.1 $3,712,214

What does Evolus, Inc. do?

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS logo
EOLS
Evolus, Inc.
$7.1

David Moatazedi insider trading

Evolus, Inc.

Mr. David Moatazedi has made 21 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 10,502 units of EOLS stock worth $113,968 on 23 Dec 2024.

The largest trade he's ever made was exercising 175,940 units of EOLS stock on 6 Jun 2024. As of 23 Dec 2024 he still owns at least 522,847 units of EOLS stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 10,502 $10.85 $113,968
Sale
Common Stock 175,940 $12.59 $2,214,557
Option
Common Stock 175,940 $7.28 $1,280,843
Option
Stock Option (Right to Buy) 175,940 $7.28 $1,280,843
Option
Stock Option (Right to Buy) 155,278 $5.46 $847,818
Option
Common Stock 155,278 $5.46 $847,818
Sale
Common Stock 155,278 $12.92 $2,006,502
Sale
Common Stock 140,214 $12.73 $1,784,644
Sale
Common Stock 16,051 $12.72 $204,121
Sale
Common Stock 6,236 $13.86 $86,431
Sale
Common Stock 96,566 $13.92 $1,344,585
Sale
Common Stock 7,706 $13.08 $100,802
Sale
Common Stock 31,300 $9.73 $304,518
Sale
Common Stock 51,348 $10.09 $517,896
Sale
Common Stock 14,778 $10.27 $151,770
Sale
Common Stock 6,110 $8.47 $51,752
Sale
Common Stock 64,211 $8.47 $543,803
Sale
Common Stock 55,321 $13.64 $754,302
Sale
Common Stock 6,104 $11.62 $70,928
Sale
Common Stock 37,972 $9.73 $369,278
Sale
Common Stock 47,737 $11.35 $541,719
Sale
Common Stock 22,708 $10.66 $242,067
Sale
Common Stock 41,763 $11.18 $466,827
Sale
Common Stock 41,763 $11.18 $466,827
Sale
Common Stock 8,310 $7.46 $61,993

Evolus key executives

Evolus, Inc. executives and other stock owners filed with the SEC:

  • Dr. Rui Avelar Dip.SportMed, M.D., C.CFP (63) Chief Medical Officer and Head of R&D
  • Mr. David Moatazedi (47) Pres, Chief Executive Officer & Director
  • Ms. Lauren P. Silvernail (67) Chief Financial Officer & Executive Vice President of Corporation Devel.